ArticleDiabetology & metabolic syndrome2026
Methodological and statistical errors distort the effects of glucagon-like peptide-1 receptor agonist drugs on body composition in patients with type 2 diabetes mellitus.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In August of 2025, Wang and colleagues published a systematic review and meta-analysis quantifying the effects of glucagon-like peptide-1 receptor agonist (GLP1RA) drugs on skeletal muscle mass in patients with type 2 diabetes mellitus. This paper is of considerable clinical importance, as sarcopenia, obesity, and diabetes are prevalent conditions of high public health interest. Despite the clinical importance of this meta-analysis, its effect estimates and conclusions are distorted by several common meta-analytic errors. A preliminary check of the article revealed errors across several steps of the meta-analytic process. The present correspondence identifies and describes specific errors related to study inclusion, risk of bias assessment, data extraction, analysis, and interpretation. In some instances, errors were severe enough to flip the conclusions derived from statistical tests. The present correspondence does not purport to identify every error in the meta-analysis by Wang and colleagues, but presents objective evidence to raise concerns that warrant clarification and correction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.